Frontiers in Immunology · 2023 · 11 citations · 35 references
Life SciencesImmunologyInfectious DiseasesAdaptive ImmunityImmunizationVaccinologyAntiviral ImmunityHumoral ImmunityVaccinationVaccine EfficacyViral VaccinesAntibodiesCoronavirus VaccinesCross-reactive ImmunityHumoral Immunity ImpairmentImprintingPre-existing ImmunitySars-cov-2 InfectionVaccine-induced Antibody Responses
Background: Pre-existing cross-reactive immunity among different coronaviruses, also termed immune imprinting, may have a comprehensive impact on subsequent SARS-CoV-2 infection and COVID-19 vaccination effectiveness. Here, we aim to explore the interplay between pre-existing seasonal coronaviruses (sCoVs) antibodies and the humoral immunity induced by COVID-19 vaccination. Methods: We first collected serum samples from healthy donors prior to COVID-19 pandemic and individuals who had received COVID-19 vaccination post-pandemic in China, and the levels of IgG antibodies against sCoVs and SARS-CoV-2 were detected by ELISA. Wilcoxon rank sum test and chi-square test were used to compare the difference in magnitude and seropositivity rate between two groups. Then, we recruited a longitudinal cohort to collect serum samples before and after COVID-19 vaccination. The levels of IgG antibodies against SARS-CoV-2 S, S1, S2 and N antigen were monitored. Association between pre-existing sCoVs antibody and COVID-19 vaccination-induced antibodies were analyzed by Spearman rank correlation. Results: 96.0% samples (339/353) showed the presence of IgG antibodies against at least one subtype of sCoVs. 229E and OC43 exhibited the highest seroprevalence rates at 78.5% and 72.0%, respectively, followed by NL63 (60.9%) and HKU1 (52.4%). The levels of IgG antibodies against two β coronaviruses (OC43 and HKU1) were significantly higher in these donors who had inoculated with COVID-19 vaccines compared to pre-pandemic healthy donors. However, we found that COVID-19 vaccine-induced antibody levels were not significant different between two groups with high levelor low level of pre-existing sCoVs antibody among the longitudinal cohort. Conclusion: We found a high prevalence of antibodies against sCoVs in Chinese population. The immune imprinting by sCoVs could be reactivated by COVID-19 vaccination, but it did not appear to be a major factor affecting the immunogenicity of COVID-19 vaccine. These findings will provide insights into understanding the impact of immune imprinting on subsequent multiple shots of COVID-19 vaccines.
35
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto, Young‐Jun Park, Martina Beltramello et al. · Nature · 2020 · 2.2K citations · Full text
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Julian Braun, Lucie Loyal, Marco Frentsch et al. · Nature · 2020 · 1.4K citations · Full text
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Kevin W. Ng, Nikhil Faulkner, Georgina H. Cornish et al. · Science · 2020 · 985 citations · Full text